Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
During the last two decades, the introduction of tyrosine kinase inhibitors (TKIs) to the therapy has changed the natural history of CML but progression into accelerated and blast phase (AP/BP) occurs in 3-5% of cases, especially in patients resistant to several lines of TKIs. In TKI-refractory pati...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Frontiers Media S.A.
2024-01-01
|
| 丛编: | Frontiers in Immunology |
| 主题: | |
| 在线阅读: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1309010/full |